GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Syncom Formulation (India) Ltd (NSE:SYNCOMF) » Definitions » 3-Year FCF Growth Rate

Syncom Formulation (India) (NSE:SYNCOMF) 3-Year FCF Growth Rate : -48.30% (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Syncom Formulation (India) 3-Year FCF Growth Rate?

Syncom Formulation (India)'s Free Cash Flow per Share for the three months ended in Mar. 2024 was ₹0.00.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -48.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Syncom Formulation (India) was 69.90% per year. The lowest was -48.30% per year. And the median was -11.35% per year.


Competitive Comparison of Syncom Formulation (India)'s 3-Year FCF Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Syncom Formulation (India)'s 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Syncom Formulation (India)'s 3-Year FCF Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Syncom Formulation (India)'s 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Syncom Formulation (India)'s 3-Year FCF Growth Rate falls into.



Syncom Formulation (India) 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Syncom Formulation (India)  (NSE:SYNCOMF) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Syncom Formulation (India) 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Syncom Formulation (India)'s 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Syncom Formulation (India) (NSE:SYNCOMF) Business Description

Traded in Other Exchanges
Address
207, Saket Nagar, Near Saket Club, Indore, MP, IND, 452018
Syncom Formulation (India) Ltd is in the business of pharmaceuticals. The company operates through three segments including manufacturing and dealings in Pharmaceutical drugs and formulations, Trading of commodities, and Renting of property. It manufactures and markets pharmaceutical formulation products in various dosage forms like tablets, capsules, liquids orals, liquids vials, ampoule injections and dry vial injections, dry syrups, ointments, inhalers, and Herbals. The company's product includes generic, antiviral, antidepressant, cough suppressant, electrolyte, histamine, estrogen, and much more. It generates maximum revenue through the Pharmaceutical drugs and formulations segment.

Syncom Formulation (India) (NSE:SYNCOMF) Headlines

No Headlines